What is Impetigo Drug Market?
Impetigo, also known as impetigo contagiosa or pyoderma, is a bacterial skin infection that is highly contagious by nature. It is considered to be one of the most common skin diseases around the world. Cases of infection in adults are rare, but minors and adolescents are more prone to the disease. In addition, people who engage in close physical contact sports such as wrestling, rugby, and American football are prone to the disease regardless of age. Impetigo is a common skin disease that infects nearly two percent of the world's population. Symptoms of impetigo include initial blisters with red bumps, sores on the skin, mostly on the face. However, in later stages, they can also be developed by other parts of the body such as the legs and arms. The blisters that appear on the skin can be irritating or sometimes painful. The wounds are mostly filled with pus that forms scabs. When scratching, the infection can spread to other areas of the skin. In addition, the likelihood of infection is higher in warm and humid conditions. Impetigo is one of the most common bacterial skin diseases and the need for medication is significantly high. The increasing incidence of the disease in recent years is favoring the global market for impetigo therapeutics. In addition, the number of minors and toddlers is increasing and is expected to have a positive impact on overall market growth. In addition, increasing awareness and low treatment costs are expected to drive the market in the coming years. For example, the introduction of improved versions of mupirocin, synthetic peptides, and ozenoxacin at a reasonable price range will benefit overall market growth.
The market study is being classified by Type (FMX-102, LTX-109, Mupirocin, Ozenoxacin and Others) and major geographies with country level break-up.
Destiny Pharma Ltd. (United Kingdom), Foamix Pharmaceuticals Ltd. (United States), Orchid Chemicals & Pharmaceuticals (India), Roche Holding AG (Switzerland), Laboratories Ojer Pharma SL (Spain), Lytix Biopharma AS (Norway), Cutanea Life Sciences (United States), GlaxoSmithKline (United Kingdom), NovaBay Pharmaceuticals (United States), LEO Pharma (Denmark) and Medimetriks Pharmaceuticals (United States) are some of the key players profiled in the study.
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Impetigo Drug market throughout the predicted period.
Analyst at AMA have segmented the market study of Global Impetigo Drug market by Type, Application and Region.
On the basis of geography, the market of Impetigo Drug has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Increasing Incidence of the Disease
- Increasing Awareness and Low Cost Of Treatment
- The Rising Population of Minors and Infants
- The Introduction of Improved Versions of Mupirocin, Synthetic Peptides and Ozenoxacin at a Reasonable Price Range
- The Growing Healthcare Infrastructure
- The Risk of Side Effects Caused By Several Medicines and Drug
- Increase in Healthcare Expenditure
- Rising Research and Development of Novel Therapeutic Drugs
- Limited Options of Advanced Medication and Therapeutics
Key Target AudienceNew Entrants/Investors, Analysts and Strategic Business Planners, Manufacturers of Impetigo Drug, Suppliers and Distributors of Impetigo Drug, Venture Capitalists and Private Equity Firms and End-Use Industry
Frequently Asked Questions (FAQ):
1. Which factors would majorly drive the Impetigo Drug Market?
"Increasing Incidence of the Disease
" is seen as one of major growth factors of Impetigo Drug Market in years to come.
2. Can we have customized study for Impetigo Drug Market?
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.